Means and methods for treating cancer

Patent metadata

Field	Value
Publication number	US-9849127-B2
Application number	US-201414890959-A
Country	US
Kind code	B2
Filing date	May 14, 2014
Priority date	May 14, 2013
Publication date	Dec 26, 2017
Grant date	Dec 26, 2017

Abstract

The present invention relates to a pharmaceutical composition comprising a compound of formula (I)

and methods of treating or preventing cell proliferation disorders comprising administering to a subject a therapeutically active amount or a preventive amount of such a compound.

First claim

The invention claimed is:

1. A method of treating or preventing a cell proliferation disorder, said method comprising the step of treating a subject suffering from or being at risk of the cell proliferation disorder with a therapeutically active amount or a preventive amount of a compound formula (I):

2. The method of claim 1 , wherein the cell proliferation disorder is leukemia, glioma, lymphoma, prostate cancer, thyroid cancer, or sarcoma.

3. The method of claim 2 , wherein the subject suffering from or being at risk of said disorder is
(a) characterized by increased expression and/or activity of at least one isoform of isocitrate dehydrogenase; or
(b) heterozygous or homozygous with regard to a mutant form of at least one isoform of isocitrate dehydrogenase.

4. The method of claim 1 , wherein the subject suffering from or being at risk of said disorder is heterozygous or homozygous with regard to a mutant form of at least one isoform of isocitrate dehydrogenase and further wherein said mutant form is characterized by one or more of the following:
(i) reduced formation of α-ketoglutarate by the encoded isocitrate dehydrogenase as compared to the wild-type isocitrate dehydrogenase;
(ii) increased formation of 2-hydroxyglutarate by the encoded isocitrate dehydrogenase as compared to the wild-type isocitrate dehydrogenase;
(iii) no increased formation of 2-hydroxyglutarate by the encoded isocitrate dehydrogenase as compared to the wild-type isocitrate dehydrogenase;
(iv) aberrant splicing such as absence of exon 7 in the spliced mRNA;
(v) a missense mutation affecting R132 in human isocitrate dehydrogenase 1;
(vi) a missense mutation affecting R172 in human isocitrate dehydrogenase 2;
(vii) a missense mutation affecting R140 in human isocitrate dehydrogenase 2;
(viii) a missense mutation affecting R100 in human isocitrate dehydrogenase 1; and
(ix) a missense mutation affecting G97 in human isocitrate dehydrogenase 1.

5. The method of claim 1 , wherein the compound is of formula (IV)

Assignees

• Medizinische Hochschule Hannover
• Medizinisch Hochschule Hannover

Inventors

• Heuser Michael
• Chaturvedi Anuhar
• Preller Matthias

Classifications

• A01K2217/052

  inducing gain of function · CPC title

• A01K67/0275

  Genetically modified vertebrates, e.g. transgenic · CPC title

• A01K2207/12

  Animals modified by administration of exogenous cells · CPC title

• A01K67/0271

  Chimeric vertebrates, e.g. comprising exogenous cells · CPC title

• A01K2227/105

  Murine · CPC title